FDA restrictions

1 articles
The Motley FoolThe Motley Fool··Rich Smith

Hims & Hers Faces Growth Deceleration as GLP-1 Market Dynamics Shift

Hims & Hers stock plunged 70% as GLP-1 market competition intensifies and growth slows. Despite challenges, company projects $2.8B 2026 revenue from diversified services.
LLYNVOHIMSearnings reportGLP-1 drugs